Report Detail

Request for Sample of this report

Other Global Value-added Medicines (VAM) Market 2026 by Company, Regions, Type and Application, Forecast to 2032

  • RnM4718553
    • |
  • 29 June, 2026
    • |
  • Global
    • |
  • 112 Pages
    • |
  • GIR
    • |
  • Other

According to our (Global Info Research) latest study, the global Value-added Medicines (VAM) market size was valued at US$ 866 million in 2025 and is forecast to a readjusted size of US$ 1784 million by 2032 with a CAGR of 11.0% during review period.
Value-added medicines offer the medical world the opportunity to increase the quality of treatments as well as expand access to healthcare for more people. By improving the efficiency of the healthcare system, value-based healthcare contributes to its sustainability, addresses inefficiencies related to medicines, and offers economic advantages to all parties involved in medical treatments.Value-added medicines are drug products and treatments created using known molecules through a process known as drug repositioning. The purpose of these innovative medicines is to create improvements in the quality of patient care.Value-based treatment options give patients more agency to manage their ailments, leading to improved patient adherence, quality of life, and health outcomes. Likewise, improved treatments prevent medical conditions to escalate to serious levels. This lightens the burden that patients in critical condition put on healthcare systems, giving doctors and nurses some much-needed breathing space.
This report is a detailed and comprehensive analysis for global Value-added Medicines (VAM) market. Both quantitative and qualitative analyses are presented by company, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2025, are provided.
Key Features:
Global Value-added Medicines (VAM) market size and forecasts, in consumption value ($ Million), 2021-2032
Global Value-added Medicines (VAM) market size and forecasts by region and country, in consumption value ($ Million), 2021-2032
Global Value-added Medicines (VAM) market size and forecasts, by Type and by Application, in consumption value ($ Million), 2021-2032
Global Value-added Medicines (VAM) market shares of main players, in revenue ($ Million), 2021-2026
The Primary Objectives in This Report Are:
To determine the size of the total market opportunity of global and key countries
To assess the growth potential for Value-added Medicines (VAM)
To forecast future growth in each product and end-use market
To assess competitive factors affecting the marketplace
This report profiles key players in the global Value-added Medicines (VAM) market based on the following parameters - company overview, revenue, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Zentiva Group, MS Pharma, Towa International, CNX Therapeutics, ROVI, Elpen, Sandoz AG, Colonis, Adamed, Hyloris Pharmaceuticals SA, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
Market segmentation
Value-added Medicines (VAM) market is split by Type and by Application. For the period 2021-2032, the growth among segments provides accurate calculations and forecasts for Consumption Value by Type and by Application. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type
Chronic Disease Treatment Drugs
Infectious Disease Treatment Drugs
Tumor Treatment Drugs
Other
Market segment by Application
Hospital
Clinic
Other
Market segment by players, this report covers
Zentiva Group
MS Pharma
Towa International
CNX Therapeutics
ROVI
Elpen
Sandoz AG
Colonis
Adamed
Hyloris Pharmaceuticals SA
TIEFENBACHER GROUP
Market segment by regions, regional analysis covers
North America (United States, Canada and Mexico)
Europe (Germany, France, UK, Russia, Italy and Rest of Europe)
Asia-Pacific (China, Japan, South Korea, India, Southeast Asia and Rest of Asia-Pacific)
South America (Brazil, Rest of South America)
Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)
The content of the study subjects, includes a total of 13 chapters:
Chapter 1, to describe Value-added Medicines (VAM) product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top players of Value-added Medicines (VAM), with revenue, gross margin, and global market share of Value-added Medicines (VAM) from 2021 to 2026.
Chapter 3, the Value-added Medicines (VAM) competitive situation, revenue, and global market share of top players are analyzed emphatically by landscape contrast.
Chapter 4 and 5, to segment the market size by Type and by Application, with consumption value and growth rate by Type, by Application, from 2021 to 2032.
Chapter 6, 7, 8, 9, and 10, to break the market size data at the country level, with revenue and market share for key countries in the world, from 2021 to 2026.and Value-added Medicines (VAM) market forecast, by regions, by Type and by Application, with consumption value, from 2027 to 2032.
Chapter 11, market dynamics, drivers, restraints, trends, Porters Five Forces analysis.
Chapter 12, the key raw materials and key suppliers, and industry chain of Value-added Medicines (VAM).
Chapter 13, to describe Value-added Medicines (VAM) research findings and conclusion.


1 Market Overview

  • 1.1 Product Overview and Scope
  • 1.2 Market Estimation Caveats and Base Year
  • 1.3 Classification of Value-added Medicines (VAM) by Type
    • 1.3.1 Overview: Global Value-added Medicines (VAM) Market Size by Type: 2021 Versus 2025 Versus 2032
    • 1.3.2 Global Value-added Medicines (VAM) Consumption Value Market Share by Type in 2025
    • 1.3.3 Chronic Disease Treatment Drugs
    • 1.3.4 Infectious Disease Treatment Drugs
    • 1.3.5 Tumor Treatment Drugs
    • 1.3.6 Other
  • 1.4 Global Value-added Medicines (VAM) Market by Application
    • 1.4.1 Overview: Global Value-added Medicines (VAM) Market Size by Application: 2021 Versus 2025 Versus 2032
    • 1.4.2 Hospital
    • 1.4.3 Clinic
    • 1.4.4 Other
  • 1.5 Global Value-added Medicines (VAM) Market Size & Forecast
  • 1.6 Global Value-added Medicines (VAM) Market Size and Forecast by Region
    • 1.6.1 Global Value-added Medicines (VAM) Market Size by Region: 2021 VS 2025 VS 2032
    • 1.6.2 Global Value-added Medicines (VAM) Market Size by Region, (2021-2032)
    • 1.6.3 North America Value-added Medicines (VAM) Market Size and Prospect (2021-2032)
    • 1.6.4 Europe Value-added Medicines (VAM) Market Size and Prospect (2021-2032)
    • 1.6.5 Asia-Pacific Value-added Medicines (VAM) Market Size and Prospect (2021-2032)
    • 1.6.6 South America Value-added Medicines (VAM) Market Size and Prospect (2021-2032)
    • 1.6.7 Middle East & Africa Value-added Medicines (VAM) Market Size and Prospect (2021-2032)

2 Company Profiles

  • 2.1 Zentiva Group
    • 2.1.1 Zentiva Group Details
    • 2.1.2 Zentiva Group Major Business
    • 2.1.3 Zentiva Group Value-added Medicines (VAM) Product and Solutions
    • 2.1.4 Zentiva Group Value-added Medicines (VAM) Revenue, Gross Margin and Market Share (2021-2026)
    • 2.1.5 Zentiva Group Recent Developments and Future Plans
  • 2.2 MS Pharma
    • 2.2.1 MS Pharma Details
    • 2.2.2 MS Pharma Major Business
    • 2.2.3 MS Pharma Value-added Medicines (VAM) Product and Solutions
    • 2.2.4 MS Pharma Value-added Medicines (VAM) Revenue, Gross Margin and Market Share (2021-2026)
    • 2.2.5 MS Pharma Recent Developments and Future Plans
  • 2.3 Towa International
    • 2.3.1 Towa International Details
    • 2.3.2 Towa International Major Business
    • 2.3.3 Towa International Value-added Medicines (VAM) Product and Solutions
    • 2.3.4 Towa International Value-added Medicines (VAM) Revenue, Gross Margin and Market Share (2021-2026)
    • 2.3.5 Towa International Recent Developments and Future Plans
  • 2.4 CNX Therapeutics
    • 2.4.1 CNX Therapeutics Details
    • 2.4.2 CNX Therapeutics Major Business
    • 2.4.3 CNX Therapeutics Value-added Medicines (VAM) Product and Solutions
    • 2.4.4 CNX Therapeutics Value-added Medicines (VAM) Revenue, Gross Margin and Market Share (2021-2026)
    • 2.4.5 CNX Therapeutics Recent Developments and Future Plans
  • 2.5 ROVI
    • 2.5.1 ROVI Details
    • 2.5.2 ROVI Major Business
    • 2.5.3 ROVI Value-added Medicines (VAM) Product and Solutions
    • 2.5.4 ROVI Value-added Medicines (VAM) Revenue, Gross Margin and Market Share (2021-2026)
    • 2.5.5 ROVI Recent Developments and Future Plans
  • 2.6 Elpen
    • 2.6.1 Elpen Details
    • 2.6.2 Elpen Major Business
    • 2.6.3 Elpen Value-added Medicines (VAM) Product and Solutions
    • 2.6.4 Elpen Value-added Medicines (VAM) Revenue, Gross Margin and Market Share (2021-2026)
    • 2.6.5 Elpen Recent Developments and Future Plans
  • 2.7 Sandoz AG
    • 2.7.1 Sandoz AG Details
    • 2.7.2 Sandoz AG Major Business
    • 2.7.3 Sandoz AG Value-added Medicines (VAM) Product and Solutions
    • 2.7.4 Sandoz AG Value-added Medicines (VAM) Revenue, Gross Margin and Market Share (2021-2026)
    • 2.7.5 Sandoz AG Recent Developments and Future Plans
  • 2.8 Colonis
    • 2.8.1 Colonis Details
    • 2.8.2 Colonis Major Business
    • 2.8.3 Colonis Value-added Medicines (VAM) Product and Solutions
    • 2.8.4 Colonis Value-added Medicines (VAM) Revenue, Gross Margin and Market Share (2021-2026)
    • 2.8.5 Colonis Recent Developments and Future Plans
  • 2.9 Adamed
    • 2.9.1 Adamed Details
    • 2.9.2 Adamed Major Business
    • 2.9.3 Adamed Value-added Medicines (VAM) Product and Solutions
    • 2.9.4 Adamed Value-added Medicines (VAM) Revenue, Gross Margin and Market Share (2021-2026)
    • 2.9.5 Adamed Recent Developments and Future Plans
  • 2.10 Hyloris Pharmaceuticals SA
    • 2.10.1 Hyloris Pharmaceuticals SA Details
    • 2.10.2 Hyloris Pharmaceuticals SA Major Business
    • 2.10.3 Hyloris Pharmaceuticals SA Value-added Medicines (VAM) Product and Solutions
    • 2.10.4 Hyloris Pharmaceuticals SA Value-added Medicines (VAM) Revenue, Gross Margin and Market Share (2021-2026)
    • 2.10.5 Hyloris Pharmaceuticals SA Recent Developments and Future Plans
  • 2.11 TIEFENBACHER GROUP
    • 2.11.1 TIEFENBACHER GROUP Details
    • 2.11.2 TIEFENBACHER GROUP Major Business
    • 2.11.3 TIEFENBACHER GROUP Value-added Medicines (VAM) Product and Solutions
    • 2.11.4 TIEFENBACHER GROUP Value-added Medicines (VAM) Revenue, Gross Margin and Market Share (2021-2026)
    • 2.11.5 TIEFENBACHER GROUP Recent Developments and Future Plans

3 Market Competition, by Players

  • 3.1 Global Value-added Medicines (VAM) Revenue and Share by Players (2021-2026)
  • 3.2 Market Share Analysis (2025)
    • 3.2.1 Market Share of Value-added Medicines (VAM) by Company Revenue
    • 3.2.2 Top 3 Value-added Medicines (VAM) Players Market Share in 2025
    • 3.2.3 Top 6 Value-added Medicines (VAM) Players Market Share in 2025
  • 3.3 Value-added Medicines (VAM) Market: Overall Company Footprint Analysis
    • 3.3.1 Value-added Medicines (VAM) Market: Region Footprint
    • 3.3.2 Value-added Medicines (VAM) Market: Company Product Type Footprint
    • 3.3.3 Value-added Medicines (VAM) Market: Company Product Application Footprint
  • 3.4 New Market Entrants and Barriers to Market Entry
  • 3.5 Mergers, Acquisition, Agreements, and Collaborations

4 Market Size Segment by Type

  • 4.1 Global Value-added Medicines (VAM) Consumption Value and Market Share by Type (2021-2026)
  • 4.2 Global Value-added Medicines (VAM) Market Forecast by Type (2027-2032)

5 Market Size Segment by Application

  • 5.1 Global Value-added Medicines (VAM) Consumption Value Market Share by Application (2021-2026)
  • 5.2 Global Value-added Medicines (VAM) Market Forecast by Application (2027-2032)

6 North America

  • 6.1 North America Value-added Medicines (VAM) Consumption Value by Type (2021-2032)
  • 6.2 North America Value-added Medicines (VAM) Market Size by Application (2021-2032)
  • 6.3 North America Value-added Medicines (VAM) Market Size by Country
    • 6.3.1 North America Value-added Medicines (VAM) Consumption Value by Country (2021-2032)
    • 6.3.2 United States Value-added Medicines (VAM) Market Size and Forecast (2021-2032)
    • 6.3.3 Canada Value-added Medicines (VAM) Market Size and Forecast (2021-2032)
    • 6.3.4 Mexico Value-added Medicines (VAM) Market Size and Forecast (2021-2032)

7 Europe

  • 7.1 Europe Value-added Medicines (VAM) Consumption Value by Type (2021-2032)
  • 7.2 Europe Value-added Medicines (VAM) Consumption Value by Application (2021-2032)
  • 7.3 Europe Value-added Medicines (VAM) Market Size by Country
    • 7.3.1 Europe Value-added Medicines (VAM) Consumption Value by Country (2021-2032)
    • 7.3.2 Germany Value-added Medicines (VAM) Market Size and Forecast (2021-2032)
    • 7.3.3 France Value-added Medicines (VAM) Market Size and Forecast (2021-2032)
    • 7.3.4 United Kingdom Value-added Medicines (VAM) Market Size and Forecast (2021-2032)
    • 7.3.5 Russia Value-added Medicines (VAM) Market Size and Forecast (2021-2032)
    • 7.3.6 Italy Value-added Medicines (VAM) Market Size and Forecast (2021-2032)

8 Asia-Pacific

  • 8.1 Asia-Pacific Value-added Medicines (VAM) Consumption Value by Type (2021-2032)
  • 8.2 Asia-Pacific Value-added Medicines (VAM) Consumption Value by Application (2021-2032)
  • 8.3 Asia-Pacific Value-added Medicines (VAM) Market Size by Region
    • 8.3.1 Asia-Pacific Value-added Medicines (VAM) Consumption Value by Region (2021-2032)
    • 8.3.2 China Value-added Medicines (VAM) Market Size and Forecast (2021-2032)
    • 8.3.3 Japan Value-added Medicines (VAM) Market Size and Forecast (2021-2032)
    • 8.3.4 South Korea Value-added Medicines (VAM) Market Size and Forecast (2021-2032)
    • 8.3.5 India Value-added Medicines (VAM) Market Size and Forecast (2021-2032)
    • 8.3.6 Southeast Asia Value-added Medicines (VAM) Market Size and Forecast (2021-2032)
    • 8.3.7 Australia Value-added Medicines (VAM) Market Size and Forecast (2021-2032)

9 South America

  • 9.1 South America Value-added Medicines (VAM) Consumption Value by Type (2021-2032)
  • 9.2 South America Value-added Medicines (VAM) Consumption Value by Application (2021-2032)
  • 9.3 South America Value-added Medicines (VAM) Market Size by Country
    • 9.3.1 South America Value-added Medicines (VAM) Consumption Value by Country (2021-2032)
    • 9.3.2 Brazil Value-added Medicines (VAM) Market Size and Forecast (2021-2032)
    • 9.3.3 Argentina Value-added Medicines (VAM) Market Size and Forecast (2021-2032)

10 Middle East & Africa

  • 10.1 Middle East & Africa Value-added Medicines (VAM) Consumption Value by Type (2021-2032)
  • 10.2 Middle East & Africa Value-added Medicines (VAM) Consumption Value by Application (2021-2032)
  • 10.3 Middle East & Africa Value-added Medicines (VAM) Market Size by Country
    • 10.3.1 Middle East & Africa Value-added Medicines (VAM) Consumption Value by Country (2021-2032)
    • 10.3.2 Turkey Value-added Medicines (VAM) Market Size and Forecast (2021-2032)
    • 10.3.3 Saudi Arabia Value-added Medicines (VAM) Market Size and Forecast (2021-2032)
    • 10.3.4 UAE Value-added Medicines (VAM) Market Size and Forecast (2021-2032)

11 Market Dynamics

  • 11.1 Value-added Medicines (VAM) Market Drivers
  • 11.2 Value-added Medicines (VAM) Market Restraints
  • 11.3 Value-added Medicines (VAM) Trends Analysis
  • 11.4 Porters Five Forces Analysis
    • 11.4.1 Threat of New Entrants
    • 11.4.2 Bargaining Power of Suppliers
    • 11.4.3 Bargaining Power of Buyers
    • 11.4.4 Threat of Substitutes
    • 11.4.5 Competitive Rivalry

12 Industry Chain Analysis

  • 12.1 Value-added Medicines (VAM) Industry Chain
  • 12.2 Value-added Medicines (VAM) Upstream Analysis
  • 12.3 Value-added Medicines (VAM) Midstream Analysis
  • 12.4 Value-added Medicines (VAM) Downstream Analysis

13 Research Findings and Conclusion

    14 Appendix

    • 14.1 Methodology
    • 14.2 Research Process and Data Source

    Summary:
    Get latest Market Research Reports on Value-added Medicines (VAM). Industry analysis & Market Report on Value-added Medicines (VAM) is a syndicated market report, published as Global Value-added Medicines (VAM) Market 2026 by Company, Regions, Type and Application, Forecast to 2032. It is complete Research Study and Industry Analysis of Value-added Medicines (VAM) market, to understand, Market Demand, Growth, trends analysis and Factor Influencing market.

    Last updated on

    REPORT YOU MIGHT BE INTERESTED

    Purchase this Report

    		$3,480.00
    		$5,220.00
    		$6,960.00
    		2,690.04
    		4,035.06
    		5,380.08
    		3,239.88
    		4,859.82
    		6,479.76
    		531,361.20
    		797,041.80
    		1,062,722.40
    		293,712.00
    		440,568.00
    		587,424.00
    Credit card Logo
    Sample Question Discount Download PDF

    Related Reports

    Reason to Buy

    • Trusted By Leaders

      Top executives from leading companies purchase research reports from us. 

    • Shop With Confidence

      We assist you with all the pre-sales enquiries related to any report so that you can buy with confidence.

    • Customer Centric

      Need assistance related to your research requirements? We are just a phone call or an email away.

    • Personalized Solutions

      Our experienced research specialists are here to help you locate the right reports for your need.

    • Secure Checkout

      Shop without being worried about safety & security of your transactions.
      •

    Request for Sample of this report

    Reports and Markets

    mcafree

    Contact Us

    +1-352-353-0818 (US)

    info@reportsandmarkets.com

    Support

    EMAIL US

    Newsletter

    KEEP UP TO DATE ON ALL THE LATEST REPORTS


    maxmind_logo